奥法木单抗单药治疗初治滤泡性淋巴瘤的2期多中心研究:CALGB 50901(Alliance)
这项2期多中心试验评估奥法木单抗单药治疗初治、低/中危FLIPI、晚期滤泡性淋巴瘤的疗效与安全性。1000 mg组36例患者的总缓解率为84%,中位无进展生存期为1.9年,中位缓解持续时间为23.7个月。延长诱导给药方案耐受性良好,活性与单药利妥昔单抗的既往报告相似。
要点
- 1000 mg组36例初治晚期FL患者的总缓解率为84%,中位PFS为1.9年。
- 1000 mg组3级输注反应发生率为25%,均为首次输注,无4级输注反应或3/4级感染。
- 延长诱导给药方案耐受性良好,单药活性与既往单药利妥昔单抗报告相似。
核心结论
- 奥法木单抗单药以延长诱导方案治疗初治、低/中危FLIPI、晚期滤泡性淋巴瘤耐受性良好且具有活性。
- 其活性似乎与既往单药利妥昔单抗的报告相似。
研究设计与样本
- 2期多中心试验(NCT01190449),纳入初治、低/中危FLIPI、晚期滤泡性淋巴瘤患者。
- 入组患者为可测量病灶的III/IV期或 bulky II期,不论GELF标准如何。
- 给药方案为每周1000 mg共4次,随后每8周一次共4次延长诱导剂量。
- 主要终点为1000 mg剂量的总缓解率,次要终点为无进展生存期和安全性。
- 共入组51例患者;15例随机分配至500 mg组,该组因入组缓慢而终止。
主要发现
- 1000 mg组36例患者的总缓解率为84%,中位无进展生存期为1.9年,中位缓解持续时间为23.7个月。
- 所有患者均存活。
- 未发生4级输注反应或3/4级感染。
- 3级输注反应仅发生在1000 mg组,发生率为25%,均为首次输注;除2例外其余患者继续研究。
- 总研究人群的停药率为6%。
局限性
- 500 mg组因入组缓慢而终止,仅15例患者被随机分配至该组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Rituximab monotherapy has proven efficacy in treatment-naïve, asymptomatic advanced-stage follicular lymphoma (FL). Ofatumumab is a fully humanized anti-CD20 monoclonal antibody with increased CD20 affinity and complement-dependent cytotoxicity. This phase 2 trial (NCT01190449) evaluated ofatumumab in patients with untreated, low/intermediate-risk FL International Prognostic Index (FLIPI), advanced-stage FL to determine single-agent efficacy. Patients with measurable disease in stages III/IV or bulky stage II, regardless of Groupe d'Etude des Lymphomes Folliculaires criteria, received 4 weekly 1000 mg doses followed by four extended induction doses once every 8 weeks. Primary endpoint was overall response rate (ORR) to 1000 mg; secondary endpoints were progression-free survival (PFS) and safety. Fifty-one patients were enrolled. Fifteen patients were randomized to 500 mg prior to discontinuing that arm for slow accrual. Among 36 patients on the 1000 mg arm, ORR was 84%, median PFS was 1·9 years and median response duration was 23·7 months. All patients remain alive. No grade 4 infusion reactions or grade 3/4 infections occurred. Grade 3 infusion reactions occurred in 25% in the 1000 mg arm only (all first infusion); all but two patients continued on study. Discontinuation was 6% for the total study population. Ofatumumab monotherapy administered by extended induction in untreated, low/intermediate-risk FLIPI, advanced-stage FL is well tolerated and active. Activity appears similar to that reported with single-agent rituximab.
引用
- Rosenbaum CA, Jung SH, Pitcher B, et al. Phase 2 multicentre study of single-agent ofatumumab in previously untreated follicular lymphoma: CALGB 50901 (Alliance). Br J Haematol. 2019. PMID: 30723894. doi:10.1111/bjh.15768
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。